AVANIR (AVNR) Higher After Zenvia Met Primary Endpoint
Up)
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) is surging higher in pre-open trading after the comapny announced that the investigational drug Zenvia met its primary efficacy endpoint in the treatment of pseudobulbar affect (PBA) in the confirmatory Phase III STAR trial.
Both Zenvia 30/10 mg and 20/10 mg provided a statistically significant reduction in episode rates over the course of the study when compared to placebo (p<0.0001). In an additional analysis of the primary endpoint, at week twelve (end of study), patients in the Zenvia 30/10 mg group reported a statistically significant mean reduction of 88% from baseline in PBA episode rates (p=0.01). Also in this study, Zenvia was generally safe and well tolerated.
Both Zenvia 30/10 mg and 20/10 mg provided a statistically significant reduction in episode rates over the course of the study when compared to placebo (p<0.0001). In an additional analysis of the primary endpoint, at week twelve (end of study), patients in the Zenvia 30/10 mg group reported a statistically significant mean reduction of 88% from baseline in PBA episode rates (p=0.01). Also in this study, Zenvia was generally safe and well tolerated.
You May Also Be Interested In
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
- Celldex (CLDX) volatility up into conference call to announce EMERGE results
- DryShips (DRYS) Trading Higher on Volatility, New Analyst Coverage
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
